Goeser T, Theilmann L
Department of Medicine, University of Heidelberg, Germany.
Int J Clin Pharmacol Ther. 1994 Nov;32(11):571-6.
Interferon is currently the only established therapeutical option for chronic viral hepatitis. Sustained response can be achieved in approximately 25% of patients with chronic HBV or HCV infection. Results in chronic HDV infection are disappointing. Whether combination of interferon with other lymphokines or antiviral drugs will lead to higher response rates, remains to be established. The argument that interferon will only place spontaneous seroconversion on an earlier date has not been disproved yet. Long-term follow-ups are necessary to show that therapy with interferon will improve survival and reduce the incidence of hepatocellular carcinoma in patients with chronic viral hepatitis.
干扰素是目前治疗慢性病毒性肝炎唯一已确立的疗法。在大约25%的慢性乙肝或丙肝感染患者中可实现持续应答。慢性丁肝病毒感染的治疗结果令人失望。干扰素与其他淋巴因子或抗病毒药物联合使用是否会带来更高的应答率,仍有待确定。关于干扰素只会使自发血清学转换提前发生的观点尚未被推翻。需要进行长期随访以证明干扰素治疗能提高慢性病毒性肝炎患者的生存率并降低肝细胞癌的发生率。